Drugs /

rituximab

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Trade Name(s):
Rituxan, Mabthera, and Truxima
NCI Definition [1]:
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for rituximab

Rituximab has been investigated in 243 clinical trials, of which 222 are open and 21 are closed. Of the trials investigating rituximab, 3 are early phase 1 (3 open), 61 are phase 1 (56 open), 42 are phase 1/phase 2 (37 open), 89 are phase 2 (82 open), 4 are phase 2/phase 3 (3 open), 42 are phase 3 (39 open), and 2 are no phase specified (2 open).

MS4A1 Expression, MYC Fusion, and BCL2 Fusion are the most frequent biomarker inclusion criteria for rituximab clinical trials.

Diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma are the most common diseases being investigated in rituximab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Rituximab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Rituximab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rituximab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Truxima, rtxm83, rituximab-abbs, rituximab biosimilar tqb2303, rituximab biosimilar sait101, rituximab biosimilar rtxm83, rituximab biosimilar pf-05280586, rituximab biosimilar jhl1101, rituximab biosimilar ibi301, rituximab biosimilar gb241, rituximab biosimilar ct-p10, rituximab biosimilar bi 695500, rituximab biosimilar abp 798, rituximab abbs, Rituxan, pf-05280586, monoclonal antibody idec-c2b8, MabThera, idec-c2b8 monoclonal antibody, idec-c2b8, idec-102, ct-p10, chimeric anti-cd20 antibody, c2b8 monoclonal antibody, bi 695500, abp 798
Drug Categories [2]:
Immunotherapies, Therapeutic antibodies
Drug Target(s) [2]:
MS4A1
NCIT ID [1]:
C1702
SNOMED ID [1]:
F-C2202

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.